| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
QuidelOrtho Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.60 |
| 52 Week High | US$84.66 |
| 52 Week Low | US$38.21 |
| Beta | 0.12 |
| 1 Month Change | -10.43% |
| 3 Month Change | -40.91% |
| 1 Year Change | -53.22% |
| 3 Year Change | -60.12% |
| 5 Year Change | -23.33% |
| Change since IPO | 942.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| QL1A | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.0% | -3.6% | -1.7% |
| 1Y | -53.2% | -3.6% | 1.4% |
Return vs Industry: QL1A underperformed the German Medical Equipment industry which returned -3.8% over the past year.
Return vs Market: QL1A underperformed the German Market which returned 1.1% over the past year.
Price Volatility
| QL1A volatility | |
|---|---|
| QL1A Average Weekly Movement | 11.7% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: QL1A's share price has been volatile over the past 3 months.
Volatility Over Time: QL1A's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 7,100 | Mike Iskra | www.quidelortho.com |
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
QuidelOrtho Corporation Fundamentals Summary
| QL1A fundamental statistics | |
|---|---|
| Market cap | €2.65b |
| Earnings (TTM) | -€9.51m |
| Revenue (TTM) | €2.82b |
0.9x
P/S Ratio-274.5x
P/E RatioIs QL1A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QL1A income statement (TTM) | |
|---|---|
| Revenue | US$3.00b |
| Cost of Revenue | US$1.50b |
| Gross Profit | US$1.49b |
| Other Expenses | US$1.50b |
| Earnings | -US$10.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 49.85% |
| Net Profit Margin | -0.34% |
| Debt/Equity Ratio | 48.4% |
How did QL1A perform over the long term?
See historical performance and comparison